In light of the findings of Hagerstrand et al. who identified SEC62 as a potential tumor-driver-gene for the development of ovarian cancer and the prognostic impact of SEC62 in other tumor entities (Hagerstrand et al., 2013), the aim of this study was to assess the role of SEC62 as a possible prognostic marker in patients with ovarian neoplasia. Here, SEC62 is linked to neoplasm.